- What's Tisch?
- Stem Cell Trial
- Get Involved
Tisch MSRCNY research scientist Dr. Roberto Alfonso, and his recent research paper around COVID-19 vaccines, were featured in an article in Managed Healthcare Executive. In the piece, Dr. Alfonso highlights the significance of the research findings, which suggest that MS patients receiving anti-CD20 therapies showed a partially-adaptive, T-cell driven immune response after receiving the COVID-19 vaccine. The article also highlights the implications this research could have for future vaccine design and application for MS patients.
You can read the full article here on the Managed Healthcare Executive website.